Patents Assigned to Ablynx N.V.
  • FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES
    Publication number: 20160263220
    Abstract: The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.
    Type: Application
    Filed: February 11, 2016
    Publication date: September 15, 2016
    Applicant: Ablynx N.V.
    Inventors: JASON E. FERNANDEZ, Daniel A. Dixon, Andrea Paulson
  • BISPECIFIC NANOBODIES
    Publication number: 20160251440
    Abstract: The present disclosure relates to bispecific polypeptides comprising a first and a second immunoglobulin single variable domain (ISV), wherein said first ISV binds to a first target on the surface of a cancer cell with a low affinity and, when bound inhibits a function of said first target, and a said second ISV binds to a second target on the surface of said cell with a high affinity and wherein said first target is different from said second target. The present invention further discloses methods for identifying and making the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: September 1, 2016
    Applicant: Ablynx N.V.
    Inventors: Annelies Roobrouck, Catelijne Stortelers, Peter Vanlandschoot, Stephanie Staelens, Miguel Conde, Hugo Soares, Dominique Schols
  • Formulations of single domain antigen binding molecules
    Patent number: 9393304
    Abstract: The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: July 19, 2016
    Assignee: Ablynx N.V.
    Inventors: Jason E. Fernandez, Daniel A. Dixon, Andrea Paulson
  • Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
    Patent number: 9382333
    Abstract: The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: July 5, 2016
    Assignee: Ablynx N.V.
    Inventors: Maria Gonzalez Pajuelo, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot
  • Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
    Patent number: 9371381
    Abstract: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: June 21, 2016
    Assignee: Ablynx, N.V.
    Inventors: Karen Silence, Marc Jozef Lauwereys, Hans De Haard
  • AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20160152693
    Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: October 29, 2015
    Publication date: June 2, 2016
    Applicant: Ablynx N.V.
    Inventors: Catelijne Stortelers, Peter Vanlandschoot, Erik Depla, Jose Melero
  • Biological materials related to c-Met
    Patent number: 9346884
    Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: May 24, 2016
    Assignee: Ablynx N.V.
    Inventors: Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer
  • Pulmonary administration of immunoglobulin single variable domains and constructs thereof
    Patent number: 9320792
    Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: April 26, 2016
    Assignee: Ablynx N.V.
    Inventors: Marie-Paule Lucienne Armanda Bouche, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
  • STABLE FORMULATIONS OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND USES THEREOF
    Publication number: 20160090424
    Abstract: The present invention relates to stable formulations of polypeptides, e.g. immunoglobulin single variable domains, in particular immunoglobulin single variable domains directed against von Willebrand Factor (vWF). The invention provides formulations which are stable upon storage for prolonged periods of time and over a broad range of temperatures. The formulations of the invention ensure a high stability of the polypeptide, allowing multiple freeze-thaw cycles without chemical or physical deterioration, and provide stability in relation to mechanical stress, such as shake, shear or stir stress. They are suitable for pharmaceutical and diagnostic preparations and compatible with pharmaceutically acceptable diluents.
    Type: Application
    Filed: May 16, 2014
    Publication date: March 31, 2016
    Applicant: Ablynx N.V.
    Inventors: Yves Meyvis, Veronique De Brabandere, Hans Ulrichts, Ann Brige, Filip Callewaert
  • Methods of using IL-6R antibodies to block or reduce binding of IL-6 to IL-6R
    Patent number: 9273150
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: March 1, 2016
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
  • Stable formulations of polypeptides and uses thereof
    Patent number: 9265834
    Abstract: Formulations are provided that contain single variable domains with a good solubility and good stability under different storage, transportation and stress conditions. The formulations are useful as pharmaceutical formulation. The formulation comprises an aqueous carrier with a pH of 5.5 to 8.0, a buffer selected from the group consisting of histidine pH 6.0-6.5, hepes pH 7.0-8.0, MES pH 6.0, succinate pH 6.0-6.5 and acetate pH 5.5-6.0; an excipient; and/or a surfactant selected from polysorbate 80, polysorbate 20 and poloxamers. The formulation is further characterized that it has an inorganic salt concentration of 150 mM or lower.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: February 23, 2016
    Assignee: Ablynx N.V.
    Inventors: Ann Brige, Christine Labeur, Veronique De Brabandere, Marc Lauwereys
  • Method for generation of immunoglobulin sequences
    Patent number: 9260508
    Abstract: The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invention relates to the generation of immunoglobulin sequences by use of DNA vaccination. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by DNA vaccination. Furthermore, the present invention relates to said immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored, such as e.g. GPCRs and ion channels, more preferably ion channels.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: February 16, 2016
    Assignee: Ablynx N.V.
    Inventors: Toon Laeremans, Catelijne Stortelers, Friedrich Nolte, Maria Gonzalez Pajuelo, Joana Assunção, Philippe Van Rompaey
  • Polypeptide constructs including VHH directed against EGFR for intracellular delivery
    Patent number: 9243065
    Abstract: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further relates to a method for delivering therapeutic molecules to the interior of cells. The invention further relates to polypeptide constructs including VHH directed against EGFR.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: January 26, 2016
    Assignee: Ablynx N.V.
    Inventors: Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen
  • Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
    Patent number: 9212226
    Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) G-protein coupled receptors (GPCRs) and in particular to CXCR4 and CXCR7, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively). Furthermore, the invention provides a new method of making amino acid sequences that are directed against transmembrane protein, and in particular for multiple spanning transmembrane proteins for which the native conformation cannot be reproduced in other “in vitro” system (e.g. GPCRs in general).
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: December 15, 2015
    Assignee: Ablynx N.V.
    Inventors: Christophe Blanchetot, Martine Smit, Regorius Leurs, Sven Jähnichen, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot
  • A-beta binding polypeptides
    Patent number: 9211330
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: December 15, 2015
    Assignee: Ablynx N.V.
    Inventors: John E. Park, Cornelia Dorner-Ciossek, Stefan Hoerer, Lothar Kussmaul, Martin Lenter, Katharina Zimmerman, Gerald Beste, Toon Laeremans, Pascal Gerard Merchiers, Jo Vercammen
  • NANOBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHA
    Publication number: 20150353635
    Abstract: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: May 12, 2015
    Publication date: December 10, 2015
    Applicant: ABLYNX N.V.
    Inventor: Els Anna Alice Beirnaert
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20150344568
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: April 29, 2015
    Publication date: December 3, 2015
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
    Patent number: 9193780
    Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: November 24, 2015
    Assignee: Ablynx N.V.
    Inventors: Anna Hultberg, Bram Maassen, Peter Vanlandschoot, Erik Depla, Catelijne Stortelers, Cornelis Theodorus Verrips, Steven Van Gucht, Jose Melero, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Robert Anthony Weiss, Nigel J. Temperton, Xavier Saelens, Bert Schepens, Alexander Szyroki, Michael Marie Harmsen
  • Nucleic acids encoding IL-6R-binding polypeptides
    Patent number: 9181350
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: November 10, 2015
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
  • BIOLOGICAL MATERIALS RELATED TO C-MET
    Publication number: 20150307612
    Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
    Type: Application
    Filed: October 1, 2012
    Publication date: October 29, 2015
    Applicant: Ablynx N.V.
    Inventors: Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer